Ikarian Capital’s Crescent Biopharma CBIO Stock Holding History

Ikarian Capital’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,728	Closed	-$518K	–	135
2024 Q1	$518K	Buy	+1,728	New	+$516K	0.06%	119

Other funds holding CBIO

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ikarian Capital's CBIO Position: Q1 2025 in Review

Ikarian Capital sold out of Crescent Biopharma (CBIO) in Q1 2025, closing a stake of 65 shares — an estimated $1.62K sold.

Ikarian Capital first reported a position in CBIO in Q4 2024 and held it in 1 quarter. The position peaked at $1.62K in Q4 2024. 35 funds tracked by Wall St. Rank hold CBIO as of Q1 2025.

Ikarian Capital reported no remaining Crescent Biopharma position as of Q1 2025 after selling out during the quarter.
Ikarian Capital sold 65 Crescent Biopharma shares in Q1 2025, an estimated $1.62K.
Ikarian Capital first reported a position in Crescent Biopharma in Q4 2024 and held it in 1 quarter.
Ikarian Capital's Crescent Biopharma position peaked at $1.62K in Q4 2024.
35 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2025.

Based on Ikarian Capital's 13F filing for Q1 2025, filed 15 May 2025.